Our Pricing

Switch to Wegovy? Complete Doses Chart & Savings Guide

Published on: June 03, 2026

Considering how to switch to wegovy uk doses chart guidance? At Cured Pharmacy, our UK-registered clinical team helps patients understand Wegovy's five-dose escalation schedule, switching protocols from other GLP-1 treatments, and transparent pricing from £79.00. Every prescription requires assessment by a UK prescriber to ensure safe, personalised weight management.

Complete Wegovy Doses Chart: UK Escalation Schedule

Wegovy (semaglutide 2.4mg) follows a structured five-dose escalation protocol designed to minimise gastrointestinal side effects whilst optimising weight loss outcomes. The MHRA-approved schedule begins at 0.25mg weekly for four weeks, then increases monthly through 0.5mg, 1mg, 1.7mg, before reaching the maintenance dose of 2.4mg weekly [1].

This gradual titration allows your body to adapt to semaglutide's effects on gastric emptying and appetite regulation. Clinical data from the STEP trials demonstrated that patients who completed the full escalation schedule experienced significantly fewer treatment discontinuations due to nausea compared to faster titration protocols [1][2].

Each Wegovy pen delivers a single pre-set dose, colour-coded for safety: yellow (0.25mg), green (0.5mg), pink (1mg), orange (1.7mg), and blue (2.4mg). Your UK prescriber will determine the appropriate starting dose based on your medical history, current medications, and previous experience with GLP-1 receptor agonists.

Dose Escalation Timeline

Month 1: 0.25mg once weekly (four doses). Month 2: 0.5mg once weekly (four doses). Month 3: 1mg once weekly (four doses). Month 4: 1.7mg once weekly (four doses). Month 5 onwards: 2.4mg once weekly (maintenance dose). If you experience persistent gastrointestinal symptoms at any stage, your prescriber may recommend delaying escalation by four weeks rather than discontinuing treatment entirely [2].

Switching to Wegovy from Ozempic or Other GLP-1 Treatments

Many UK patients switch to Wegovy from Ozempic (semaglutide 1mg), Saxenda (liraglutide), or compounded semaglutide formulations. The switching protocol depends on your current medication and dose. Patients transitioning from Ozempic 1mg typically move directly to Wegovy 1.7mg for four weeks before escalating to the 2.4mg maintenance dose, as both contain the same active ingredient [3].

If you're switching from Saxenda (liraglutide 3mg daily), your prescriber will likely start you at Wegovy 0.5mg or 1mg weekly, depending on how well you tolerated liraglutide. The pharmacokinetic profiles differ significantly—semaglutide has a 165-hour half-life compared to liraglutide's 13 hours—so allowing a washout period of 24-48 hours between final liraglutide dose and first Wegovy injection is standard practice [3].

Patients using compounded or unlicensed semaglutide products should discuss their current regimen transparently with their UK prescriber. Dosing accuracy, sterility standards, and excipient profiles vary considerably outside licensed pharmaceutical channels, and your prescriber may recommend starting at a lower Wegovy dose to establish consistent therapeutic levels.

What to Expect During the Transition

Most patients switching between GLP-1 medications experience minimal disruption to weight loss progress. In clinical practice, we observe that patients transitioning from Ozempic to Wegovy often achieve an additional 3-5% body weight reduction over the subsequent 12 weeks as they reach the higher 2.4mg maintenance dose [1]. Mild nausea or changes in bowel habits may occur during the first two weeks of switching, but these typically resolve as steady-state semaglutide levels stabilise.

Wegovy Pricing and Savings at Cured Pharmacy

Wegovy is available at Cured Pharmacy from £79.00, with transparent upfront pricing displayed before your free online consultation. Unlike some UK providers who reveal costs only after assessment, we believe patients deserve clarity on treatment investment from the outset. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures all pricing reflects genuine UK-licensed medication dispensed from our GPhC-registered premises (9012511).

The total monthly cost depends on your prescribed dose. During escalation months, you'll receive four single-dose pens corresponding to that month's strength. Once you reach the 2.4mg maintenance dose, most patients continue at this level long-term, though some prescribers adjust dosing based on individual response and tolerability.

We guarantee the lowest prices in the UK for genuine licensed Wegovy. If you find a lower advertised price from another UK-registered pharmacy for the same product, we'll match it. All orders include free discreet delivery, with no hidden consultation fees or subscription charges—what you see is what you pay.

How Wegovy Works: Semaglutide Mechanism of Action

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a naturally occurring hormone involved in appetite regulation and glucose metabolism. When injected subcutaneously once weekly, semaglutide binds to GLP-1 receptors in the brain's hypothalamus, reducing hunger signals and increasing satiety after meals [1].

Semaglutide also slows gastric emptying, meaning food remains in your stomach longer, prolonging feelings of fullness. This dual mechanism—central appetite suppression and peripheral gastric delay—produces average weight reductions of 15-20% over 68 weeks in clinical trials, significantly higher than lifestyle modification alone [1][2].

The 2.4mg weekly dose in Wegovy represents the optimal balance between efficacy and tolerability established through the STEP clinical programme. Lower doses (0.5mg, 1mg) produce modest weight loss but fall short of the clinically meaningful reductions seen at the licensed maintenance dose. Higher experimental doses showed no additional benefit but increased gastrointestinal adverse events [2].

Who Can Switch to Wegovy? UK Eligibility Criteria

Wegovy is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea. NICE guidance supports its use as part of a comprehensive weight management programme including dietary modification and increased physical activity [4].

You may not be suitable for Wegovy if you have a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or diabetic retinopathy requiring active treatment. Pregnant or breastfeeding women should not use Wegovy, and women of childbearing potential should use reliable contraception, discontinuing treatment at least two months before planned conception [4].

Our UK prescribers conduct thorough medical assessments during your free online consultation, reviewing your full medication list, previous weight loss attempts, and any contraindications. The consultation typically takes under three minutes to complete, with most patients receiving a prescribing decision within 24 hours. All assessments comply with GMC and GPhC standards for remote prescribing.

Switching from NHS to Private Wegovy Supply

Some patients initiated on Wegovy through NHS specialist weight management services choose to continue treatment privately due to supply constraints or service capacity limitations. If you're switching from NHS to private supply, bring documentation of your current dose and treatment duration to your consultation. Your private prescriber will maintain continuity of care, ensuring you receive the correct pen strength without unnecessary dose adjustments. Cured Pharmacy works collaboratively with NHS colleagues—we never encourage patients to abandon NHS care, but we provide a reliable supply option when NHS pathways face delays.

Managing Side Effects During Dose Escalation

Gastrointestinal side effects—particularly nausea, diarrhoea, and constipation—are the most commonly reported adverse events during Wegovy treatment, affecting approximately 44% of patients in the STEP trials [2]. These symptoms typically peak during the first few weeks after each dose increase and diminish as your body adapts to higher semaglutide levels.

To minimise nausea, inject Wegovy on an empty stomach or after a light meal, avoid high-fat foods for 2-3 hours post-injection, and stay well-hydrated throughout the day. Eating smaller, more frequent meals rather than three large meals helps reduce gastric distension. Ginger tea, peppermint, and avoiding strong food odours can provide symptomatic relief during the adjustment period [3].

If side effects become intolerable at any dose level, contact your prescriber before your next injection. Extending the current dose for an additional four weeks often allows tolerance to develop without abandoning treatment. Fewer than 7% of patients in clinical trials discontinued Wegovy due to adverse events when dose escalation was managed flexibly [2]. Your UK clinical team at Cured Pharmacy remains available for ongoing support throughout your treatment journey.

When to Seek Medical Advice

Seek urgent medical attention if you experience severe persistent abdominal pain (especially radiating to the back), persistent vomiting preventing fluid intake, signs of pancreatitis, or symptoms of thyroid tumours such as a neck lump or difficulty swallowing. These serious adverse events are rare but require immediate clinical evaluation. For routine side effect management or dosing questions, contact our pharmacy team on (+44) 116 4646009 during business hours, or use the consultation portal for non-urgent queries.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
3. Novo Nordisk Limited. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity: Technology appraisal guidance [TA875]. NICE. Retrieved from https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to treatment, dietary modification, and physical activity levels.